Sign in

    Stefan Quenneville

    Research Analyst at Venton Financial

    Stefan Quenneville is an analyst at Venton Financial, specializing in equity research within the medical technology and healthcare services sectors. He has covered companies such as Quipt Home Medical Corp., participating in earnings calls and providing insights into sector developments and company performance. While performance metrics and aggregate ranking data are not publicly available, his research contributions have been noted in recent corporate reports. Quenneville's prior career history, industry tenure, and professional credential details are not disclosed in current public sources.

    Stefan Quenneville's questions to Quipt Home Medical (QIPT) leadership

    Stefan Quenneville's questions to Quipt Home Medical (QIPT) leadership • Q3 2024

    Question

    Stefan Quenneville of Venton Financial questioned the operational impact of GLP-1 drugs, asking specifically if insurance payers are requiring patients to try CPAP therapy first before approving GLP-1s for off-label sleep apnea treatment due to the significant cost difference.

    Answer

    CEO Gregory Crawford responded that Quipt has not observed a trend of insurance companies mandating CPAP therapy prior to GLP-1 reimbursement. Instead, he highlighted recent data from a major device manufacturer showing that patients prescribed a GLP-1 are 10.7% more likely to start PAP therapy. Crawford suggested this indicates that GLP-1s are acting as a complementary tailwind, bringing more health-conscious individuals into the healthcare system to address all their conditions, including sleep apnea.

    Ask Fintool Equity Research AI